Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Emraclidine in Healthy Adults
NCT03217604Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Placebo with PF-06852231 (2 arms). Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs), Number of Participants With Laboratory Abnormalities and 3 more. Started Jul 2017; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03217604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217604.